Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Currently, predicting dose distributions through neural networks can improve the automation level of radiotherapy planning. However, a single neural network often has limitations in its ability to extract features and obtain clinical information.

Purpose: To assist in the development of volumetric modulated arc therapy (VMAT) plans for non-small cell lung cancer (NSCLC) patients, a dual-branch feature extraction neural network is proposed to predict dose distributions.

Methods: This study proposes a dual-branch feature extraction network named CTNet, which consists of a convolutional network and a transformer network in parallel to extract local and global features that are meaningful for dose prediction tasks. A feature fusion module has been developed to reduce the heterogeneity of the two extracted features. To promote the learning of two types of features in the network, weighted mean square error and multiscale structural loss were used. The network was trained on 144 VMAT plans of NSCLC patients. The performance of this network was compared with that of several commonly used networks, and the network performance was evaluated on the basis of the voxel-level mean absolute error (MAE) within the planning target volume (PTV) and organs at risk (OARs), as well as the error in clinical dose‒volume metrics.

Results: The MAE between the predicted dose distribution and the manually planned dose distribution within the PTV was 1.14 Gy, and the D95 error was less than 1 Gy. Compared with the other four commonly used networks, the dose error of the CTNet was the smallest in the PTV and OARs.

Conclusions: The proposed CTNet uses the transformer and convolutional networks to extract global information, such as the relative position of the PTV and OARs, as well as local information, such as shape and size, enabling accurate prediction of the dose distribution for NSCLC patients undergoing VMAT radiotherapy.

Download full-text PDF

Source
http://dx.doi.org/10.1002/mp.17775DOI Listing

Publication Analysis

Top Keywords

dose distribution
16
dual-branch feature
12
feature extraction
12
nsclc patients
12
network
10
lung cancer
8
dose
8
extraction network
8
neural network
8
vmat plans
8

Similar Publications

Pharmacokinetics of carprofen in Siamese crocodiles (Crocodylus siamensis).

Res Vet Sci

September 2025

Department of Pharmacology, Faculty of Veterinary Medicine, Kasetsart University, Bangkok, Thailand. Electronic address:

Carprofen (CAR) is an NSAID commonly used in veterinary medicine that preferentially inhibits cyclooxygenase-2 (COX-2), thereby mitigating inflammation and pain while minimizing adverse effects linked to cyclooxygenase-1 (COX-1) inhibition. This study characterizes the pharmacokinetics of CAR in Siamese crocodiles (Crocodylus siamensis) and was conducted at an ambient temperature range of 27-30 °C following single intravenous (IV) or intramuscular (IM) administration at 2 mg/kg, and IM administration at 4 mg/kg. Plasma concentrations were determined using a validated high-performance liquid chromatography method with ultraviolet detection (HPLC-UV).

View Article and Find Full Text PDF

A myotropic AAV vector combined with skeletal muscle -regulatory elements improve glycogen clearance in mouse models of Pompe disease.

Mol Ther Methods Clin Dev

June 2025

Université Paris-Saclay, University Evry, Inserm, Genethon, Integrare Research Unit UMR_S951, 91000 Evry, France.

Pompe disease is a glycogen storage disorder caused by mutations in the acid α-glucosidase (GAA) gene, leading to reduced GAA activity and glycogen accumulation in heart and skeletal muscles. Enzyme replacement therapy with recombinant GAA, the standard of care for Pompe disease, is limited by poor skeletal muscle distribution and immune responses after repeated administrations. The expression of GAA in muscle with adeno-associated virus (AAV) vectors has shown limitations, mainly the low targeting efficiency and immune responses to the transgene.

View Article and Find Full Text PDF

Bietti crystalline dystrophy (BCD) is an autosomal recessive disorder caused by loss-of-function mutations in the gene, characterized by crystal-like lipid deposits in the retina, progressive photoreceptor loss, and retinal pigment epithelium (RPE) deterioration. Currently, there are no approved treatments for BCD. VGR-R01, an investigational gene therapy, uses subretinal administration of recombinant adeno-associated virus type 8 (AAV8) vector to deliver the human CYP4V2 gene.

View Article and Find Full Text PDF

Digital twins in nuclear medicine: A proposition of a modular pipeline for dosimetry protocol optimization in molecular radiotherapy.

Comput Struct Biotechnol J

August 2025

Institut de Recherche en Cancérologie de Montpellier (IRCM), Équipe Labellisée Ligue Contre le Cancer, INSERM U1194, Université de Montpellier, Institut régional du Cancer de Montpellier (ICM), Montpellier, France.

Digital twins (DTs) are emerging tools for simulating and optimizing therapeutic protocols in personalized nuclear medicine. In this paper, we present a modular pipeline for constructing patient-specific DTs aimed at assessing and improving dosimetry protocols in PRRT such as therapy. The pipeline integrates three components: (i) an anatomical DT, generated by registering patient CT scans with an anthropomorphic model; (ii) a functional DT, based on a physiologically-based pharmacokinetic (PBPK) model created in SimBiology; and (iii) a virtual clinical trial module using GATE to simulate particle transport, image simulation, and absorbed dose distribution.

View Article and Find Full Text PDF

Background: Another approach to improve the dose conformity is to use charged particles like protons instead of the conventional X- and γ-rays. Protons exhibit a specific depth-dose distribution which allows to achieve a more targeted dose deposition and a significant sparing of healthy tissue behind the tumor. In particular, proton therapy has, therefore, become a routinely prescribed treatment for tumors located close to sensitive structures.

View Article and Find Full Text PDF